Resolution of severe diarrhoea and return to work in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)

被引：0
|
作者：
Lord H. [1 ,2 ]
机构：
[1] University of Montréal, Montréal, Que.
[2] Maisonneuve Rosemont, University of Montréal, Montréal, Que. HIT 2M4
来源：
Drugs | 2006年 / 66卷 / Suppl 2期
关键词：
Sirolimus; Risedronate; Mycophenolate Mofetil; Graft Function; Darbepoetin Alfa;
D O I：
10.2165/00003495-200666002-00004
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：11 / 13
页数：2
相关论文
共 50 条
  • [21] Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease
    Jones, Rachel B.
    Walsh, Michael
    Chaudhry, Afzal N.
    Smith, Kenneth G. C.
    Jayne, David R. W.
    CLINICAL KIDNEY JOURNAL, 2014, 7 (06): : 562 - 568
  • [22] Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children
    Pape, Lars
    Ahlenstiel, Thurid
    Kreuzer, Martin
    Ehrich, Jochen H. H.
    PEDIATRIC TRANSPLANTATION, 2008, 12 (06) : 640 - 642
  • [23] Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function
    Meneses, Rejane de Paula
    Kotsifas, Cecilia Halusch
    PEDIATRIC TRANSPLANTATION, 2009, 13 (02) : 188 - 193
  • [24] Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic®)
    Budde, K.
    Knoll, G.
    Curtis, J.
    Chan, L.
    Pohanka, E.
    Gentil, M.
    Seifu, Y.
    Marrast, A. -C.
    Neumayer, H. -H.
    CLINICAL NEPHROLOGY, 2006, 66 (02) : 103 - 111
  • [25] Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation
    Langone, Anthony
    Shihab, Fuad
    Pankewycz, Oleh
    Doria, Cataldo
    Wiland, Anne
    McCague, Kevin
    Chan, Laurence
    CLINICAL TRANSPLANTATION, 2014, 28 (09) : 961 - 967
  • [26] Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil
    Lopez-Solis, Roberto
    DeVera, Michael
    Steel, Jennifer
    Fedorek, Sheila
    Sturdevant, Mark
    Hughes, Christopher
    Humar, Abhinav
    CLINICAL TRANSPLANTATION, 2014, 28 (07) : 783 - 788
  • [27] Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients
    Graff, Jochen
    Scheuermann, Ernst-Heinrich
    Brandhorst, Gunnar
    Oellerich, Michael
    Gossmann, Jan
    THERAPEUTIC DRUG MONITORING, 2016, 38 (03) : 388 - 392
  • [28] Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation
    Shehata, Magdi
    Bhandari, Sunil
    Venkat-Raman, Gopalakrishnan
    Moore, Richard
    D'Souza, Richard
    Riad, Hany
    Bakran, Ali
    Baker, Richard
    Needham, Christine
    Andrews, Christopher
    TRANSPLANT INTERNATIONAL, 2009, 22 (08) : 821 - 830
  • [29] Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients
    Hummel, Manfred
    Yonan, Nizar
    Ross, Heather
    Miller, Leslie W.
    Sechaud, Romain
    Balez, Sebastien
    Koelle, Ernst Ulrich
    Gerosa, Gino
    CLINICAL TRANSPLANTATION, 2007, 21 (01) : 18 - 23
  • [30] Comparing Outcomes Associated With Dose Manipulations of Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant Recipients
    Cooper, Matthew
    Deering, Kathleen L.
    Slakey, Douglas P.
    Harshaw, Qing
    Arcona, Stephen
    McCann, Erin L.
    Rasetto, Flavia A.
    Florman, Sander S.
    TRANSPLANTATION, 2009, 88 (04) : 514 - 520
12345